Thalidomide-NH-C8-NH2 hydrochloride

Background Introduction

Thalidomide-NH-C8-NH2 hydrochloride is a specialized E3 ligase ligand-linker conjugate designed for advanced PROTAC (Proteolysis Targeting Chimera) research. It comprises a thalidomide-based moiety known to recruit the cereblon (CRBN) E3 ubiquitin ligase, linked via an eight-carbon alkyl chain terminated with an amine group (NH2) for ready conjugation. The hydrochloride form enhances its solubility and stability, making it exceptionally useful for the construction of bespoke PROTAC molecules.

Mechanism

This molecule functions as a bifunctional PROTAC linker component. The thalidomide motif binds to the CRBN E3 ligase, facilitating the recruitment of ubiquitin-proteasome machinery. The C8 alkyl chain serves as an optimal linker, providing spatial flexibility and chemical reactivity through its terminal amine group. Researchers can utilize this amine handle to attach a variety of target protein-binding ligands via amide coupling or other chemoselective conjugation strategies. When incorporated into a complete PROTAC, Thalidomide-NH-C8-NH2 hydrochloride effectively enables the targeted ubiquitination and subsequent degradation of disease-relevant proteins.

Applications

Thalidomide-NH-C8-NH2 hydrochloride is widely applied in medicinal chemistry, drug discovery, and targeted protein degradation research. Its primary application is as a building block for the synthesis of custom PROTAC molecules targeting proteins implicated in cancer, neurodegenerative diseases, and immune disorders. The compound's chemical structure allows for rapid and efficient assembly of CRBN-based PROTACs, facilitating structure-activity relationship (SAR) studies, high-throughput screening, and the development of next-generation therapeutic agents. It is a valuable tool for both academic and industrial researchers aiming to harness the full potential of targeted protein degradation technologies.

• Long-chain amine linker (C8) improves solubility and flexibility in PROTAC design, enabling efficient target engagement.
• Ideal for CRBN-based PROTAC synthesis, ensuring high stability and robust E3 ligase recruitment.

Thalidomide-NH-C8-NH2 hydrochloride serves as a versatile E3 Ligase Ligand-Linker Conjugate in PROTACs, facilitating targeted protein degradation by linking the E3 ligase to a specific protein of interest. The following provides a detailed description of this molecule, focusing on the linker, ligand, and selection of target protein ligands.

Linker: The linker in Thalidomide-NH-C8-NH2 hydrochloride is characterized by an eight-carbon alkyl chain, offering moderate flexibility and stability. This non-cleavable linker ensures a robust connection between the ligand and the target protein ligand, enhancing the efficiency of the PROTAC complex.

Ligand: The ligand in this molecule is derived from thalidomide, a well-characterized E3 ligase recruiter. Its phthalimide moiety is crucial for binding to the cereblon E3 ligase, facilitating the ubiquitination and subsequent degradation of the target protein.

Reactive Site: The primary reactive site is the terminal amine group, which can couple with target protein ligands through amide bond formation. Recommended reaction types include amidation or peptide coupling reactions, which are efficient and reliable for creating stable conjugates.

Recommended Target Protein Ligand: A compatible warhead for this molecule would be an electrophilic group that can form a covalent bond with the reactive amine. This approach enhances specificity and stability of the PROTAC complex, making it suitable for applications in studying protein function and validating therapeutic targets in vitro.